Skip to main content
PMC home page
The Western Journal of Medicine logoLink to The Western Journal of Medicine
. 1992 Aug;157(2):154–157.

Erythropoietin therapy in patients with chronic renal failure.

A J Pinevich 1, J Petersen 1
PMCID: PMC1011236  PMID: 1441466

Abstract

Symptomatic anemia is a common complication of chronic renal failure. Treatment is now possible with the availability of recombinant human erythropoietin (epoetin alfa). Previous experimental studies have suggested that correcting the anemia of chronic renal failure may be harmful in that renal failure may be accelerated. Although experience with this drug has been primarily restricted to its use in patients with end-stage renal disease, several recent trials have been reported in patients with varying degrees of chronic renal failure. We review these studies with particular reference to the progression of renal failure and the drug's reported side effects. We conclude that the use of epoetin is beneficial and well tolerated and that there is no compelling evidence for the acceleration of renal failure associated with its use in patients.

Full text

PDF
155

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abels R. Rate of progression of chronic renal failure in predialysis patients treated with erythropoietin. Semin Nephrol. 1990 Mar;10(2 Suppl 1):20–25. [PubMed] [Google Scholar]
  2. Abraham P. A., Opsahl J. A., Rachael K. M., Asinger R., Halstenson C. E. Renal function during erythropoietin therapy for anemia in predialysis chronic renal failure patients. Am J Nephrol. 1990;10(2):128–136. doi: 10.1159/000168067. [DOI] [PubMed] [Google Scholar]
  3. Brown C. D., Friedman E. A. Clinical and blood rheologic stability in erythropoietin-treated predialysis patients. Am J Nephrol. 1990;10 (Suppl 2):29–33. doi: 10.1159/000168214. [DOI] [PubMed] [Google Scholar]
  4. Brown C. D., Kieran M., Thomas L. L., Zhao Z. H., Larsen R., Friedman E. A. Treatment of azotemic, nonoliguric, anemic patients with human recombinant erythropoietin raises whole-blood viscosity proportional to hematocrit. Nephron. 1991;59(3):394–398. doi: 10.1159/000186597. [DOI] [PubMed] [Google Scholar]
  5. Cannella G., La Canna G., Sandrini M., Gaggiotti M., Nordio G., Movilli E., Maiorca R. Renormalization of high cardiac output and of left ventricular size following long-term recombinant human erythropoietin treatment of anemic dialyzed uremic patients. Clin Nephrol. 1990 Dec;34(6):272–278. [PubMed] [Google Scholar]
  6. Delano B. G. Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients. Am J Kidney Dis. 1989 Aug;14(2 Suppl 1):14–18. [PubMed] [Google Scholar]
  7. Erslev A. J. Erythropoietin. N Engl J Med. 1991 May 9;324(19):1339–1344. doi: 10.1056/NEJM199105093241907. [DOI] [PubMed] [Google Scholar]
  8. Eschbach J. W., Abdulhadi M. H., Browne J. K., Delano B. G., Downing M. R., Egrie J. C., Evans R. W., Friedman E. A., Graber S. E., Haley N. R. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med. 1989 Dec 15;111(12):992–1000. doi: 10.7326/0003-4819-111-12-992. [DOI] [PubMed] [Google Scholar]
  9. Eschbach J. W., Adamson J. W. Guidelines for recombinant human erythropoietin therapy. Am J Kidney Dis. 1989 Aug;14(2 Suppl 1):2–8. [PubMed] [Google Scholar]
  10. Eschbach J. W., Kelly M. R., Haley N. R., Abels R. I., Adamson J. W. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med. 1989 Jul 20;321(3):158–163. doi: 10.1056/NEJM198907203210305. [DOI] [PubMed] [Google Scholar]
  11. Eschbach J. W. The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int. 1989 Jan;35(1):134–148. doi: 10.1038/ki.1989.18. [DOI] [PubMed] [Google Scholar]
  12. Flaharty K. K., Grimm A. M., Vlasses P. H. Epoetin: human recombinant erythropoietin. Clin Pharm. 1989 Nov;8(11):769–782. [PubMed] [Google Scholar]
  13. Frenken L. A., Verberckmoes R., Michielsen P., Koene R. A. Efficacy and tolerance of treatment with recombinant-human erythropoietin in chronic renal failure (pre-dialysis) patients. Nephrol Dial Transplant. 1989;4(9):782–786. [PubMed] [Google Scholar]
  14. Garcia D. L., Anderson S., Rennke H. G., Brenner B. M. Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass. Proc Natl Acad Sci U S A. 1988 Aug;85(16):6142–6146. doi: 10.1073/pnas.85.16.6142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kleinman K. S., Schweitzer S. U., Perdue S. T., Bleifer K. H., Abels R. I. The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: a double-blind, placebo-controlled trial. Am J Kidney Dis. 1989 Dec;14(6):486–495. doi: 10.1016/s0272-6386(89)80149-0. [DOI] [PubMed] [Google Scholar]
  16. Lafferty H. M., Anderson S., Brenner B. M. Anemia: a potent modulator of renal hemodynamics in models of progressive renal disease. Am J Kidney Dis. 1991 May;17(5 Suppl 1):2–7. [PubMed] [Google Scholar]
  17. Lim V. S., DeGowin R. L., Zavala D., Kirchner P. T., Abels R., Perry P., Fangman J. Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial. Ann Intern Med. 1989 Jan 15;110(2):108–114. doi: 10.7326/0003-4819-110-2-108. [DOI] [PubMed] [Google Scholar]
  18. Lim V. S., Kirchner P. T., Fangman J., Richmond J., DeGowin R. L. The safety and the efficacy of maintenance therapy of recombinant human erythropoietin in patients with renal insufficiency. Am J Kidney Dis. 1989 Dec;14(6):496–506. doi: 10.1016/s0272-6386(89)80150-7. [DOI] [PubMed] [Google Scholar]
  19. Löw I., Grützmacher P., Bergmann M., Schoeppe W. Echocardiographic findings in patients on maintenance hemodialysis substituted with recombinant human erythropoietin. Clin Nephrol. 1989 Jan;31(1):26–30. [PubMed] [Google Scholar]
  20. Mitch W. E., Walser M., Buffington G. A., Lemann J., Jr A simple method of estimating progression of chronic renal failure. Lancet. 1976 Dec 18;2(7999):1326–1328. doi: 10.1016/s0140-6736(76)91974-7. [DOI] [PubMed] [Google Scholar]
  21. Myers B. D., Deen W. M., Robertson C. R., Brenner B. M. Dynamics of glomerular ultrafiltration in the rat. VIII. Effects of hematocrit. Circ Res. 1975 Mar;36(3):425–435. doi: 10.1161/01.res.36.3.425. [DOI] [PubMed] [Google Scholar]
  22. Nissenson A. R. Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency, and quality of life. Semin Nephrol. 1989 Mar;9(1 Suppl 2):25–31. [PubMed] [Google Scholar]
  23. Onoyama K., Kumagai H., Takeda K., Shimamatsu K., Fujishima M. Effects of human recombinant erythropoietin on anaemia, systemic haemodynamics and renal function in predialysis renal failure patients. Nephrol Dial Transplant. 1989;4(11):966–970. doi: 10.1093/ndt/4.11.966. [DOI] [PubMed] [Google Scholar]
  24. Paganini E. P., Garcia J., Abdulhadi M., Lathim D., Giesman J., Weick J. K. The anemia of chronic renal failure. Overview and early erythropoietin experience. Cleve Clin J Med. 1989 Jan-Feb;56(1):79–86. doi: 10.3949/ccjm.56.1.79. [DOI] [PubMed] [Google Scholar]
  25. Paganini E. P., Latham D., Abdulhadi M. Practical considerations of recombinant human erythropoietin therapy. Am J Kidney Dis. 1989 Aug;14(2 Suppl 1):19–25. [PubMed] [Google Scholar]
  26. Schwartz A. B., Kelch B., Terzian L., Prior J., Kim K. E., Pequinot E., Kahn S. B. One year of rHuEPO therapy prolongs RBC survival and may stabilize RBC membranes despite natural progression of chronic renal failure to uremia and need for dialysis. ASAIO Trans. 1990 Jul-Sep;36(3):M691–M696. [PubMed] [Google Scholar]
  27. Sheingold S. H., Churchill D. N., Muirhead N., Laupacis A. Recombinant human erythropoietin: factors to consider in cost-benefit analysis. Am J Kidney Dis. 1991 Jan;17(1):86–92. doi: 10.1016/s0272-6386(12)80258-7. [DOI] [PubMed] [Google Scholar]
  28. Spear G. S. Implications of the glomerular lesions of cyanotic congenital heart disease. J Chronic Dis. 1966 Oct;19(10):1083–1088. doi: 10.1016/0021-9681(66)90141-x. [DOI] [PubMed] [Google Scholar]
  29. Spivak J. L. Erythropoietin: a brief review. Nephron. 1989;52(4):289–294. doi: 10.1159/000185665. [DOI] [PubMed] [Google Scholar]
  30. Sundal E., Kaeser U. Correction of anaemia of chronic renal failure with recombinant human erythropoietin: safety and efficacy of one year's treatment in a European multicentre study of 150 haemodialysis-dependent patients. Nephrol Dial Transplant. 1989;4(11):979–987. doi: 10.1093/ndt/4.11.979. [DOI] [PubMed] [Google Scholar]
  31. Walser M., Drew H. H., LaFrance N. D. Reciprocal creatinine slopes often give erroneous estimates of progression of chronic renal failure. Kidney Int Suppl. 1989 Nov;27:S81–S85. [PubMed] [Google Scholar]
  32. de Jong P. E., Weening J. J., Donker A. J., van der Hem G. K. The effect of phlebotomy on renal function and proteinuria in a patient with congenital cyanotic heart disease. Nephron. 1983;33(3):225–226. doi: 10.1159/000182948. [DOI] [PubMed] [Google Scholar]

Articles from Western Journal of Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES